1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Skelton, N.J.
Koehler, M.F.T.
Zobel, K.
Wong, W.L.
Yeh, S.
Pisabarro, M.T.
Yin, J.P.
Lasky, L.A.
Sidhu, S.S.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
J.Biol.Chem.
JBCHA3
0071
0021-9258
278
7645
7654
10.1074/jbc.M209751200
12446668
Origins of PDZ domain ligand specificity. Structure determination and mutagenesis of the Erbin PDZ domain.
2003
10.2210/pdb1n7t/pdb
pdb_00001n7t
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
1
SINGLE WAVELENGTH
M
1
1.0
11196.597
99-mer peptide of densin-180-like protein
Erbin pdz domain
1
man
polymer
the peptide is related to the C-termini of the p120-like catenins.
877.939
phage-derived peptide
1
syn
polymer
no
no
GSHMGHELAKQEIRVRVEKDPELGFSISGGVGGRGNPFRPDDDGIFVTRVQPEGPASKLLQPGDKIIQANGYSFINIEHG
QAVSLLKTFQNTVELIIVREVSS
GSHMGHELAKQEIRVRVEKDPELGFSISGGVGGRGNPFRPDDDGIFVTRVQPEGPASKLLQPGDKIIQANGYSFINIEHG
QAVSLLKTFQNTVELIIVREVSS
A
polypeptide(L)
no
no
TGWETWV
TGWETWV
B
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
human
Homo
Escherichia
Escherichia coli
sample
erbin
9606
Homo sapiens
511693
Escherichia coli BL21
BL21
plasmid
pET15b
database_2
pdbx_nmr_software
pdbx_struct_assembly
pdbx_struct_oper_list
struct_ref_seq_dif
repository
Initial release
Version format compliance
Version format compliance
Data collection
Database references
Derived calculations
1
0
2003-01-28
1
1
2008-04-28
1
2
2011-07-13
1
3
2022-02-23
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_nmr_software.name
_struct_ref_seq_dif.details
SEQUENCE
The phage-derived peptide, chain B,
is de novo design. No sequence
database reference is available for
the peptide.
RCSB
Y
RCSB
2002-11-16
REL
REL
THE PEPTIDE WAS CHEMICALLY SYNTHESIZED. IT WAS selected from A phage display library.
sample
The resonance assignments were determined using triple-resonance NMR spectroscopy.
least violation of experimental restraints
100
20
3D_15N-separated_NOESY
HNHA
3D HNHB
3D 15N-separated low mixing time TOCSY
2D-15N-filtered NOESY
3D_13C-separated_NOESY
3D-13_filtered, 13C-edited NOESY
2D-13C-filtered NOESY
250 mM
6.5
1
atm
298
K
250 mM
6.5
1
atm
298
K
250 mM
6.5
1
atm
298
K
250 mM
6.5
1
atm
298
K
The complex was determined using a total of 1717 NOE distance restraints
(148 intra residue, 339 sequential, 328 medium range, 699 long-range and 203 intermolecular),
36 hydrogen bond restraints,
156 dihedral angle restraints (86 phi, 44 psi and 26 chi-1)
and 82 15N residual dipolar coupling restraints.
The best 20 conformers (of 100) had no distance violations greater than 0.12A
and no dihedral angle violations greater than 3.0 degrees.
RMSD from experimental distance restraints was 0.0055+/-0.0007.
The mean backbone rmsd from the mean structure was 0.40+/- 0.05 A for N, Ca and C atoms of residues 10-100.
74% (25%) of residues were in the most favoured (allowed) region of phi/psi space;
no residues were in the disallowed region.
torsion angle dynamics,
simulated annealing
2
closest to the average
2 mM Erbin PDZ (15N) + 2.2 mM peptide;
25 mM sodium phosphate pH 6.5;
50 mM sodium chloride
90% H2O, 10% D20
2 mM Erbin PDZ (15N,13C) + 2.2 mM peptide;
25 mM sodium phosphate pH 6.5;
50 mM sodium chloride
90% H2O, 10% D20
2 mM Erbin PDZ (15N,13C) + 2.2 mM peptide;
25 mM sodium phosphate pH 6.5;
50 mM sodium chloride
100% D2O
2 mM Erbin PDZ (15N) + 2.2 mM peptide;
25 mM sodium phosphate pH 6.5;
50 mM sodium chloride;
15 mg/ml Pf1 phage
90% H2O, 10% D20
bruker
collection
XwinNMR
3.1
Accelrys
data analysis
Felix
98
Accelrys
refinement
CNS
2000.1
600
Bruker
DRX
800
Bruker
DRX
GLY
1
n
1
GLY
1
A
SER
2
n
2
SER
2
A
HIS
3
n
3
HIS
3
A
MET
4
n
4
MET
4
A
GLY
5
n
5
GLY
5
A
HIS
6
n
6
HIS
6
A
GLU
7
n
7
GLU
7
A
LEU
8
n
8
LEU
8
A
ALA
9
n
9
ALA
9
A
LYS
10
n
10
LYS
10
A
GLN
11
n
11
GLN
11
A
GLU
12
n
12
GLU
12
A
ILE
13
n
13
ILE
13
A
ARG
14
n
14
ARG
14
A
VAL
15
n
15
VAL
15
A
ARG
16
n
16
ARG
16
A
VAL
17
n
17
VAL
17
A
GLU
18
n
18
GLU
18
A
LYS
19
n
19
LYS
19
A
ASP
20
n
20
ASP
20
A
PRO
21
n
21
PRO
21
A
GLU
22
n
22
GLU
22
A
LEU
23
n
23
LEU
23
A
GLY
24
n
24
GLY
24
A
PHE
25
n
25
PHE
25
A
SER
26
n
26
SER
26
A
ILE
27
n
27
ILE
27
A
SER
28
n
28
SER
28
A
GLY
29
n
29
GLY
29
A
GLY
30
n
30
GLY
30
A
VAL
31
n
31
VAL
31
A
GLY
32
n
32
GLY
32
A
GLY
33
n
33
GLY
33
A
ARG
34
n
34
ARG
34
A
GLY
35
n
35
GLY
35
A
ASN
36
n
36
ASN
36
A
PRO
37
n
37
PRO
37
A
PHE
38
n
38
PHE
38
A
ARG
39
n
39
ARG
39
A
PRO
40
n
40
PRO
40
A
ASP
41
n
41
ASP
41
A
ASP
42
n
42
ASP
42
A
ASP
43
n
43
ASP
43
A
GLY
44
n
44
GLY
44
A
ILE
45
n
45
ILE
45
A
PHE
46
n
46
PHE
46
A
VAL
47
n
47
VAL
47
A
THR
48
n
48
THR
48
A
ARG
49
n
49
ARG
49
A
VAL
50
n
50
VAL
50
A
GLN
51
n
51
GLN
51
A
PRO
52
n
52
PRO
52
A
GLU
53
n
53
GLU
53
A
GLY
54
n
54
GLY
54
A
PRO
55
n
55
PRO
55
A
ALA
56
n
56
ALA
56
A
SER
57
n
57
SER
57
A
LYS
58
n
58
LYS
58
A
LEU
59
n
59
LEU
59
A
LEU
60
n
60
LEU
60
A
GLN
61
n
61
GLN
61
A
PRO
62
n
62
PRO
62
A
GLY
63
n
63
GLY
63
A
ASP
64
n
64
ASP
64
A
LYS
65
n
65
LYS
65
A
ILE
66
n
66
ILE
66
A
ILE
67
n
67
ILE
67
A
GLN
68
n
68
GLN
68
A
ALA
69
n
69
ALA
69
A
ASN
70
n
70
ASN
70
A
GLY
71
n
71
GLY
71
A
TYR
72
n
72
TYR
72
A
SER
73
n
73
SER
73
A
PHE
74
n
74
PHE
74
A
ILE
75
n
75
ILE
75
A
ASN
76
n
76
ASN
76
A
ILE
77
n
77
ILE
77
A
GLU
78
n
78
GLU
78
A
HIS
79
n
79
HIS
79
A
GLY
80
n
80
GLY
80
A
GLN
81
n
81
GLN
81
A
ALA
82
n
82
ALA
82
A
VAL
83
n
83
VAL
83
A
SER
84
n
84
SER
84
A
LEU
85
n
85
LEU
85
A
LEU
86
n
86
LEU
86
A
LYS
87
n
87
LYS
87
A
THR
88
n
88
THR
88
A
PHE
89
n
89
PHE
89
A
GLN
90
n
90
GLN
90
A
ASN
91
n
91
ASN
91
A
THR
92
n
92
THR
92
A
VAL
93
n
93
VAL
93
A
GLU
94
n
94
GLU
94
A
LEU
95
n
95
LEU
95
A
ILE
96
n
96
ILE
96
A
ILE
97
n
97
ILE
97
A
VAL
98
n
98
VAL
98
A
ARG
99
n
99
ARG
99
A
GLU
100
n
100
GLU
100
A
VAL
101
n
101
VAL
101
A
SER
102
n
102
SER
102
A
SER
103
n
103
SER
103
A
THR
301
n
1
THR
301
B
GLY
302
n
2
GLY
302
B
TRP
303
n
3
TRP
303
B
GLU
304
n
4
GLU
304
B
THR
305
n
5
THR
305
B
TRP
306
n
6
TRP
306
B
VAL
307
n
7
VAL
307
B
author_defined_assembly
2
dimeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
A
N
VAL
15
A
N
VAL
15
A
O
LEU
95
A
O
LEU
95
A
O
ILE
96
A
O
ILE
96
A
N
GLN
68
A
N
GLN
68
A
N
ALA
69
A
N
ALA
69
A
O
TYR
72
A
O
TYR
72
A
O
PHE
46
A
O
PHE
46
A
N
SER
28
A
N
SER
28
A
N
ILE
27
A
N
ILE
27
B
O
THR
305
B
O
THR
5
1
A
ALA
9
-171.00
-171.17
1
A
ASP
20
-166.98
89.06
1
A
PRO
37
-92.85
34.90
1
A
GLN
51
-103.91
-68.09
1
A
PRO
55
-60.20
-70.03
1
A
ALA
56
-99.02
43.40
1
A
LEU
59
-91.62
-69.52
1
A
ASN
70
46.47
29.00
1
A
GLN
90
-65.65
-137.75
1
B
TRP
303
-169.89
-42.25
2
A
SER
2
-162.44
-47.28
2
A
ALA
9
-144.48
44.20
2
A
LYS
10
-174.65
-179.27
2
A
ASP
20
-175.29
84.02
2
A
GLN
51
-102.66
-67.89
2
A
PRO
55
-58.26
-76.43
2
A
SER
57
-107.35
-67.25
2
A
ASN
76
61.23
62.36
2
A
PHE
89
-48.98
172.70
2
A
GLN
90
-84.31
-143.46
3
A
ALA
9
-102.14
-158.43
3
A
ASP
20
-173.97
85.52
3
A
GLN
51
-102.86
-69.95
3
A
LEU
59
-92.23
-65.11
3
A
GLN
90
-62.59
-131.40
3
A
ASN
91
-82.59
-72.28
4
A
GLU
7
-113.90
66.80
4
A
ALA
9
-102.25
47.88
4
A
ASP
20
-175.10
84.87
4
A
ASN
36
-173.54
142.30
4
A
PRO
37
-90.42
39.87
4
A
PHE
38
-125.62
-53.44
4
A
GLN
51
-97.13
-70.41
4
A
LEU
59
-92.04
-72.61
4
A
ASN
76
62.54
73.78
4
A
PHE
89
-47.87
172.81
4
A
GLN
90
-92.50
-138.00
4
A
ASN
91
-78.96
-74.97
5
A
LEU
8
-106.79
-84.74
5
A
ALA
9
-174.96
35.58
5
A
ASP
20
-163.59
86.87
5
A
ASN
36
-170.74
132.69
5
A
PRO
37
-91.52
44.15
5
A
PHE
38
-122.84
-57.77
5
A
GLN
51
-104.87
-68.17
5
A
PRO
55
-57.05
-76.11
5
A
SER
57
-99.73
-63.27
5
A
PRO
62
-63.79
79.06
5
A
ASP
64
-96.24
-158.25
5
A
ASN
70
46.72
29.27
5
A
GLN
90
-66.72
-136.60
6
A
ASP
20
-171.11
88.22
6
A
ASP
43
-100.03
64.62
6
A
GLN
51
-104.97
-68.45
6
A
PRO
55
-58.89
-76.82
6
A
SER
57
-105.04
-67.45
6
A
PRO
62
-68.80
73.79
6
A
ASN
70
46.47
29.77
6
A
ASN
76
62.81
75.77
6
A
PHE
89
-46.67
170.85
6
A
GLN
90
-88.56
-142.23
6
B
TRP
303
-161.68
-43.94
7
A
LEU
8
-97.39
-63.10
7
A
LYS
10
-172.78
117.86
7
A
PHE
38
-133.92
-51.37
7
A
GLN
51
-104.38
-67.82
7
A
PRO
55
-59.57
-74.45
7
A
ALA
56
-106.90
46.76
7
A
SER
57
-108.54
-60.39
7
A
LEU
59
-93.23
-63.35
7
A
ASN
76
64.24
74.17
7
A
PHE
89
-45.56
170.99
7
A
GLN
90
-84.56
-143.01
7
B
TRP
303
-162.52
-158.97
7
B
GLU
304
-69.54
-179.64
8
A
HIS
3
-57.79
108.22
8
A
GLU
7
-125.56
-159.21
8
A
LEU
8
-56.42
109.97
8
A
ALA
9
-151.92
-144.28
8
A
LYS
10
-43.88
108.05
8
A
ASP
20
-173.75
83.45
8
A
ASP
43
-102.18
40.82
8
A
GLN
51
-104.55
-68.71
8
A
PRO
55
-58.59
-71.93
8
A
ALA
56
-105.87
47.34
8
A
LEU
59
-92.60
-64.87
8
A
PHE
89
-46.74
170.90
8
A
GLN
90
-83.85
-142.85
8
A
ASN
91
-79.48
-70.30
9
A
ALA
9
-103.34
61.80
9
A
ASP
20
-175.85
81.39
9
A
ARG
34
-173.12
-42.22
9
A
ASP
43
-106.79
66.70
9
A
GLN
51
-105.54
-68.99
9
A
PRO
55
-58.63
-78.06
9
A
ALA
56
-117.06
53.96
9
A
SER
57
-108.14
-65.12
9
A
ASN
76
61.87
74.88
9
A
GLN
90
-65.18
-136.65
9
A
ASN
91
-80.30
-70.36
10
A
SER
2
-152.04
-63.32
10
A
MET
4
-141.17
-47.55
10
A
HIS
6
-157.99
-48.35
10
A
ALA
9
-169.29
-161.34
10
A
ASP
20
-174.65
82.72
10
A
GLN
51
-102.10
-69.67
10
A
PRO
55
-59.70
-77.49
10
A
ALA
56
-106.80
49.57
10
A
SER
57
-100.86
-61.41
10
A
ASN
70
45.62
28.18
10
A
PHE
89
-47.54
171.38
10
A
GLN
90
-77.53
-145.60
11
A
SER
2
-148.86
33.31
11
A
GLU
7
-68.80
-174.24
11
A
LYS
10
-174.89
125.46
11
A
ASP
20
-172.84
85.70
11
A
GLN
51
-104.99
-67.92
11
A
PRO
55
-60.98
-75.41
11
A
ALA
56
-108.15
47.52
11
A
ASN
76
61.09
70.82
11
A
ASN
91
-134.60
-81.95
12
A
LEU
8
-144.63
35.73
12
A
ALA
9
-88.98
-146.09
12
A
LYS
10
-44.20
107.79
12
A
ASP
20
-169.37
86.89
12
A
ASP
41
-155.41
18.91
12
A
ASP
43
-89.61
40.64
12
A
GLN
51
-96.02
-68.07
12
A
PRO
55
-57.96
-73.74
12
A
ASN
76
61.46
70.41
12
A
PHE
89
-49.09
173.66
12
A
GLN
90
-87.84
-140.25
12
A
SER
102
-162.42
102.01
12
B
TRP
303
-147.67
20.73
13
A
HIS
6
-147.77
-72.33
13
A
ASP
20
-174.95
83.35
13
A
PRO
37
-93.42
34.19
13
A
GLN
51
-102.77
-71.34
13
A
ALA
56
-108.56
45.25
13
A
LEU
59
-95.48
-65.34
13
A
ASP
64
-67.77
-177.66
13
A
ASN
76
63.18
72.75
13
A
PHE
89
-46.88
174.70
13
A
GLN
90
-85.79
-143.69
13
A
ASN
91
-81.15
-70.71
13
B
TRP
303
-165.28
-42.04
14
A
GLU
7
-141.78
28.60
14
A
ASP
20
-175.89
78.12
14
A
ARG
34
-178.35
-77.29
14
A
ASP
43
-108.44
42.39
14
A
GLN
51
-105.31
-68.24
14
A
PRO
55
-59.67
-74.46
14
A
LEU
59
-91.24
-65.14
14
A
ASN
76
62.17
76.47
14
A
GLN
90
-63.29
-139.31
15
A
MET
4
-90.00
-62.89
15
A
LYS
19
-105.70
74.95
15
A
VAL
31
-151.40
81.38
15
A
GLN
51
-105.25
-68.81
15
A
ASN
70
45.13
27.64
15
A
ASN
76
61.11
76.86
15
A
PHE
89
-51.06
176.40
15
A
GLN
90
-82.08
-144.00
16
A
LEU
8
-170.83
-41.71
16
A
ALA
9
-64.17
-160.05
16
A
LYS
10
-51.46
102.86
16
A
LYS
19
-112.30
73.28
16
A
ASN
36
-173.89
132.86
16
A
ASP
43
-102.30
64.52
16
A
GLN
51
-104.73
-68.30
16
A
PRO
55
-58.57
-72.52
16
A
PRO
62
-64.15
71.16
16
A
ASN
76
62.13
75.93
16
A
PHE
89
-49.74
177.02
16
A
GLN
90
-82.17
-144.83
17
A
ASP
20
-171.98
85.57
17
A
PRO
37
-92.33
30.32
17
A
ASP
43
-98.88
54.82
17
A
GLN
51
-105.06
-68.85
17
A
PRO
55
-60.07
-75.81
17
A
ALA
56
-104.05
46.06
17
A
ASN
70
42.56
28.87
17
A
ASN
76
61.29
73.78
17
A
PHE
89
-47.82
173.55
17
A
GLN
90
-81.38
-145.58
18
A
SER
2
-160.44
33.08
18
A
HIS
6
-165.56
33.70
18
A
GLN
51
-104.86
-68.23
18
A
PRO
55
-58.32
-76.44
18
A
ALA
56
-115.32
50.95
18
A
ASN
76
63.30
76.17
18
A
GLN
90
-65.77
-105.34
18
A
ASN
91
-88.40
-83.04
19
A
GLU
7
-115.02
72.29
19
A
ALA
9
-167.29
37.85
19
A
LYS
19
-106.32
74.93
19
A
GLN
51
-100.21
-68.41
19
A
PRO
55
-58.27
-78.26
19
A
ALA
56
-108.19
46.88
19
A
SER
57
-101.95
-61.43
19
A
ASN
70
49.32
29.11
19
A
GLN
90
-61.72
-145.55
20
A
ALA
9
-107.71
49.74
20
A
ASP
20
-172.18
83.09
20
A
ASP
43
-104.42
44.63
20
A
GLN
51
-104.35
-67.77
20
A
PRO
55
-57.58
-77.07
20
A
ALA
56
-118.34
51.80
20
A
ASN
70
45.67
28.46
20
A
ASN
76
61.64
71.88
20
A
PHE
89
-48.52
171.62
20
A
GLN
90
-86.99
-142.47
20
B
TRP
303
-145.98
16.54
ERBIN PDZ domain bound to a phage-derived peptide
1
N
N
2
N
N
A
GLU
78
A
GLU
78
HELX_P
A
PHE
89
A
PHE
89
1
1
12
SIGNALING PROTEIN
pdz domain, c-terminal peptide complex, high affnity ligand, SIGNALING PROTEIN
A
ASP
20
A
ASP
20
1
A
PRO
21
A
PRO
21
0.51
A
ASP
20
A
ASP
20
2
A
PRO
21
A
PRO
21
0.42
A
ASP
20
A
ASP
20
3
A
PRO
21
A
PRO
21
0.46
A
ASP
20
A
ASP
20
4
A
PRO
21
A
PRO
21
0.37
A
ASP
20
A
ASP
20
5
A
PRO
21
A
PRO
21
0.47
A
ASP
20
A
ASP
20
6
A
PRO
21
A
PRO
21
0.51
A
ASP
20
A
ASP
20
7
A
PRO
21
A
PRO
21
0.42
A
ASP
20
A
ASP
20
8
A
PRO
21
A
PRO
21
0.24
A
ASP
20
A
ASP
20
9
A
PRO
21
A
PRO
21
0.54
A
ASP
20
A
ASP
20
10
A
PRO
21
A
PRO
21
0.41
A
ASP
20
A
ASP
20
11
A
PRO
21
A
PRO
21
0.65
A
ASP
20
A
ASP
20
12
A
PRO
21
A
PRO
21
0.68
A
ASP
20
A
ASP
20
13
A
PRO
21
A
PRO
21
0.45
A
ASP
20
A
ASP
20
14
A
PRO
21
A
PRO
21
0.50
A
ASP
20
A
ASP
20
15
A
PRO
21
A
PRO
21
0.41
A
ASP
20
A
ASP
20
16
A
PRO
21
A
PRO
21
0.43
A
ASP
20
A
ASP
20
17
A
PRO
21
A
PRO
21
0.62
A
ASP
20
A
ASP
20
18
A
PRO
21
A
PRO
21
0.31
A
ASP
20
A
ASP
20
19
A
PRO
21
A
PRO
21
0.23
A
ASP
20
A
ASP
20
20
A
PRO
21
A
PRO
21
0.19
LAP2_HUMAN
UNP
1
1314
Q96RT1
GHELAKQEIRVRVEKDPELGFSISGGVGGRGNPFRPDDDGIFVTRVQPEGPASKLLQPGDKIIQANGYSFINIEHGQAVS
LLKTFQNTVELIIVREVSS
1N7T
PDB
2
1N7T
1314
1412
1N7T
5
103
Q96RT1
A
1
5
103
301
307
1N7T
301
307
1N7T
B
2
1
7
1
cloning artifact
GLY
1
1N7T
A
Q96RT1
UNP
1
1
cloning artifact
SER
2
1N7T
A
Q96RT1
UNP
2
1
cloning artifact
HIS
3
1N7T
A
Q96RT1
UNP
3
1
cloning artifact
MET
4
1N7T
A
Q96RT1
UNP
4
4
3
anti-parallel
anti-parallel
anti-parallel
anti-parallel
anti-parallel
A
ILE
13
A
ILE
13
A
GLU
18
A
GLU
18
A
THR
92
A
THR
92
A
VAL
98
A
VAL
98
A
LYS
65
A
LYS
65
A
ALA
69
A
ALA
69
A
TYR
72
A
TYR
72
A
SER
73
A
SER
73
A
ILE
45
A
ILE
45
A
PHE
46
A
PHE
46
A
SER
26
A
SER
26
A
GLY
29
A
GLY
29
B
THR
305
B
THR
5
B
TRP
306
B
TRP
6